Zerviate Approved to Treat Allergic Conjunctivitis

May 30, 2017 – The U.S. FDA has approved Zerviate™ (cetirizine ophthalmic solution) 0.24%, manufactured by Nicox.  Zerviate is indicated to reduce itching of the eyes caused by allergic conjunctivitis (eye inflammation from pollen or other irritants). Recommended dosing is one drop into the affected eye(s) once a day.

Although cetirizine, a second-generation antihistamine, has been available in oral forms for more than 20 years, Zerviate is the first eye drop formulation. Nicox has not announced launch or pricing plans for Zerviate.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

• Complete and submit the report Online: www.fda.gov/medwatch/report.htm
• U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.